Document is current

Article History

Received: 25 November 2025

Accepted: 30 March 2026

First Online: 10 April 2026

Declarations

:

: The trial was approved by the institutional review board or independent ethics committee at each center and all participants provided informed consent.

: Not applicable.

: EA, TY, KW, SW, KH, PB, ET, JA, AC, AR, DV, NS, JZ, and LR are employees of Eisai. KH is an Eisai-sponsored voluntary research associate professor at Washington University.KH, NRB, RJB received income based on technology (Methods to detect MTBR tau isoforms and use thereof; PCT/US2020/046224) licensed by Washington University to C2N Diagnostics.BAG reports no financial disclosures or conflicts of interest.SF reports no financial disclosures or conflicts of interest.TLSB has received research support from Avid Radiopharmaceuticals, Siemens, and Hyperfine (to institution); consulted for Biogen, Eli Lilly, Eisai, Bristol Myers Squibb and Merck; travel support from Eisai, J&J; and received speaking/education fees from Medscape, PeerView and Neurology Today.RJB receives lab research funding from the National Institutes of Health, Alzheimer’s Association, BrightFocus Foundation, Rainwater Foundation, Association for Frontotemporal Degeneration FTD Biomarkers Initiative, Avid Radiopharmaceuticals, Janssen, Tau Consortium, Novartis, Centene Corporation, Association for Frontotemporal Degeneration, the Cure Alzheimer’s Fund, Coins for Alzheimer’s Research Trust Fund, The Foundation for Barnes‐Jewish Hospital, Good Ventures Foundation, DIAN‐TU Pharma Consortium, Tau SILK Consortium (AbbVie, Biogen, Eli Lilly and Company and an anonymous organization), the NfL Consortium (AbbVie, Biogen, Bristol Meyers Squibb, Hoffman La Roche), and the Tracy Family SILQ Center. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive income based on technology (stable isotope labeling kinetics, blood plasma assay, and methods of diagnosing AD with phosphorylation changes) licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board.EM has received research funding from the National Institute of Health, Eli Lilly, Hoffman‐La Roche, Eisai, the Alzheimer Association, and GHR. He has served as consultant/advisor for Ionis, Hoffman‐La Roche, Alzamend, Sanofi, and AstraZeneca. He has served as a DSMB member for Alector and Alnylum and is on the scientific advisory board for Foundation Alzheimer. CM received consulting fees from Lilly as expert advisor in development of clinical program of siRNA J4T‐MCL‐0LAA; received honoraria for sponsored symposia: (a) Scientific symposium on novel DMTs in dementia; (b) educational symposium on DMTs from Lilly; received honoraria for sponsored symposium at ABN on implementation of lecanemab in UK from Eisai; received paid registration fee and travel for UK National neurology conference (ABN) from Esiai, and paid registration and travel for AAIC as a Scientific Program Committee from Alzheimer’s Association; and reports the following: Lilly – member of advisory board on donanemab Trailblazer; Novartis – member of advisory board on AD drug program steering committee; Roche/Genentech – member of advisory board for trontinemab, Eisai – member of advisory board on UK AUR for Leqembi, Chair data safety monitoring board Immunobrain, Biogen – advisor on program steering committee EMBARK/ENVISION aducanumab, Biogen – advisor on program steering committee and PI for phase II CELIA BIIB080, and Eisai – chair of AUR development UK committee for lecanemab.